John Libbey Eurotext

European Cytokine Network


IL-8 as a potential biomarker in Guillain-Barre Syndrome Volume 30, numéro 4, December 2019


  • Figure 1
  • Figure 2


1 Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland
2 Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
3 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
4 Department of Medicine, Division of Immunology and Allergy, Geneva University Hospitals, Geneva, Switzerland
* Correspondence

This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.